WO2023166096 - METHODS OF ADMINISTERING FVIII MIMETIC BISPECIFIC ANTIBODIES ONCE MONTHLY
National phase entry:
Publication Number
WO/2023/166096
Publication Date
07.09.2023
International Application No.
PCT/EP2023/055240
International Filing Date
01.03.2023
Title **
[English]
METHODS OF ADMINISTERING FVIII MIMETIC BISPECIFIC ANTIBODIES ONCE MONTHLY
[French]
PROCÉDÉS D'ADMINISTRATION D'ANTICORPS BISPÉCIFIQUES MIMÉTIQUES DE FVIII UNE FOIS PAR MOIS
Applicants **
NOVO NORDISK HEALTH CARE AG
The Circle 32/38
CH-8058 Zürich, CH
Inventors
MATYTSINA, Irina Alekseyevna
Novo Alle 1
2880 Bagsværd, DK
KREILGÅRD, Mads
Novo Alle 1
2880 Bagsværd, DK
Priority Data
22159642.2
02.03.2022
EP
22159643.0
02.03.2022
EP
22212144.4
08.12.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1535 | |
| EPO | Filing, Examination | 6255 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 8710 |
Total: 17730 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention generally relates to the use of bispecific FVIII mimetic antibodies in treatment of haemophilia such as haemophilia A with or without inhibitors and in particular methods for the treatment of the disease such as dosage regimens and compositions for use in such methods.[French]
La présente invention concerne de manière générale l'utilisation d'anticorps mimétiques de FVIII bispécifiques dans le traitement de l'hémophilie telle que l'hémophilie A avec ou sans inhibiteurs et en particulier des procédés pour le traitement de la maladie tels que des régimes posologiques ainsi que des compositions destinées à être utilisées dans de tels procédés.